Gregor Diagnostics Inc., a molecular diagnostics company developing a groundbreaking at-home screening test for prostate cancer, today announced the closing of a $900k round of seed financing.
The new patient-friendly test Gregor is developing will be the first non-invasive way to accurately detect prostate cancer at the earliest stages. Critically, it will also be the first diagnostic to distinguish between different forms of the cancer, so treatment can be tailored accordingly. As a result, Gregor will be able to accurately send men with more aggressive prostate cancer to life-saving treatment, while also sparing any unnecessary and potentially risky invasive biopsies and treatments for men with indolent forms of the disease.
“Prostate cancer is the second deadliest cancer for men in the US,” said Gregor Diagnostics CEO, Tobias Zutz. “In fact, according to the American Cancer Society, prostate cancer deaths are expected to be up 9% in 2018. But screening rates have actually been declining since 2008. That’s largely due to shortcomings and inaccuracies with the current screening methods,” Mr. Zutz said. “And that means that we are missing aggressive prostate cancers where early detection can save lives. We started Gregor because we believe that we shouldn’t just abandon prostate cancer screening altogether, but rather we should go out there and develop a better screening test ourselves.” Read the full release here.